Levels of circulating CD33+CD11b+HLA-DR−/low subsets in CRC patients were also significantly higher compared with HDs as shown in Figure 1B (CRC: 78.2 ± 2.7% and HD: 70.9 ± 2.4%). This evidence concerns the gene CD33 and colorectal carcinoma.